

Case Number:	CM15-0141108		
Date Assigned:	07/28/2015	Date of Injury:	02/07/2008
Decision Date:	09/01/2015	UR Denial Date:	07/07/2015
Priority:	Standard	Application Received:	07/20/2015

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/Service. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

The Expert Reviewer has the following credentials:

State(s) of Licensure: Colorado

Certification(s)/Specialty: Family Practice

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

This injured worker is a 51 year old male who reported an industrial injury on 2/7/2008. His diagnoses, and or impression, were noted to include: chronic pain; opioid dependence; and status-post lumbosacral discectomy and fusion. His treatments were noted to include physical therapy, medication management with toxicology studies; and rest from work. The progress notes of 5/15/2015 reported persistent pain in the lower back with left radicular pain, numbness/tingling in the left lower extremity. Objective findings were noted to include tenderness and limited range of motion in the lumbar spine, with positive straight leg raise. The physician's requests for treatments were noted to include the continuation of Norco for pain and increased dose Gabapentin for neuropathic pain.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Norco 10/325mg #180: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Page(s): 78, 91.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Pain Interventions and Treatments Page(s): 79-80, 85, 88-89, 93.

Decision rationale: The Guidelines establish criteria for use of opioids, including long-term use (6 months or more). When managing patients using long-term opioids, the following should be addressed: Re-assess the diagnosis and review previous treatments and whether or not they were helpful. When re-assessing, pain levels and improvement in function should be documented. Pain levels should be documented every visit. Function should be evaluated every 6 months using a validated tool. Adverse effects, including hyperalgesia, should also be addressed each visit. Patient's motivation and attitudes about pain / work / interpersonal relationships can be examined to determine if patient requires psychological evaluation as well. Aberrant / addictive behavior should be addressed if present. Do not decrease dose if effective. Medication for breakthrough pain may be helpful in limiting overall medication. Follow up evaluations are recommended every 1-6 months. To summarize the above, the 4A's of Drug Monitoring (analgesia, activities of daily living, adverse side effects, and aberrant drug-taking Behaviors) have been established. The monitoring of these outcomes over time should affect therapeutic decisions and provide a framework for documentation of the clinical use of these controlled drugs. (Passik, 2000) Several circumstances need to be considered when determining to discontinue opioids: 1) Verify patient has not had failure to improve because of inappropriate dosing or under-dosing of opioids. 2) Consider possible reasons for immediate discontinuation including diversion, prescription forgery, illicit drug use, suicide attempt, arrest related to opioids, and aggressive or threatening behavior in clinic. Weaning from the medication over 30 day period, under direct medical supervision, is recommended unless a reason for immediate discontinuation exists. If a medication contract is in place, some physicians will allow one infraction without immediate discontinuation, but the contract and clinic policy should be reviewed with patient and consequences of further violations made clear to patient. 3) Consider discontinuation if there has been no improvement in overall function, or a decrease in function. 4) Patient has evidence of unacceptable side effects. 5) Patient's pain has resolved. 6) Patient exhibits "serious non-adherence." Per the Guidelines, Chelminski defines "serious substance misuse" or non-adherence as meeting any of the following criteria: (a) cocaine or amphetamines on urine toxicology screen (positive cannabinoid was not considered serious substance abuse); (b) procurement of opioids from more than one provider on a regular basis; (c) diversion of opioids; (d) urine toxicology screen negative for prescribed drugs on at least two occasions (an indicator of possible diversion); & (e) urine toxicology screen positive on at least two occasions for opioids not routinely prescribed. (Chelminski, 2005) 7) Patient requests discontinuing opioids. 8) Consider verifying that patient is in consultation with physician specializing in addiction to consider detoxification if patient continues to violate the medication contract or shows other signs of abuse / addiction. 9) Document the basis for decision to discontinue opioids. Likewise, when making the decision to continue opioids long term, consider the following: Has patient returned to work? Has patient had improved function and decreased pain with the opioids? For the patient of concern, there is documentation that pain contract was given to the patient as of 5/15/2015, months or even years after Norco initiated / continued. Other notes in the records do indicate that pain management was discussed, and CURES searched for outside prescriptions, but there is no documentation that pain agreement was in place at those times. Urine drug screens were included in the records for review. (2 consistent and 1 not consistent. The records do not include a discussion of the inconsistent UDS) All of the primary treating physician notes indicate no change in patient's pain over time. There is no objective evaluation of functional improvement documented. Without documentation of improvement in pain and function over time, and without appropriate discussions of possible aberrant drug taking behavior (inconsistent UDS) documented, the Norco is not approved as medically necessary. Abrupt discontinuation of opioid therapy is not medically necessary.

Gabapentin 300mg #60 with 2 refills: Overturned

Claims Administrator guideline: Decision based on MTUS ACOEM Chapter 12 Low Back Complaints, Chronic Pain Treatment Guidelines.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Pain Interventions and Treatments Page(s): 16-19.

Decision rationale: Per the guidelines, Gabapentin, an anti-epileptic drug, is recommended for treatment of neuropathic pain, as is the class of anti-epilepsy drugs (AED's). These drugs have been most studied for treatment of post herpetic neuralgia and diabetic neuropathy. Because neuropathic pain is often multifactorial with variable symptoms and physical findings, there is a lack of agreement among experts on the best treatment. There is also a lack of quality evidence for any specific treatment for neuropathic pain with most randomized control trials addressing the above-mentioned post-herpetic neuralgia and other polyneuropathies, and few randomized control trials for central pain, none for treatment of radicular pain. As there is a lack of good evidence / expert agreement, per the guidelines, the choice of a specific agent for treatment of neuropathic pain and the decision to continue treatment with a specific anti-epileptic drug are generally determined by efficacy of the medication and any adverse reactions experienced. When using anti-epileptic drugs for treatment of neuropathic pain, the guidelines define a "good" response to the use of AEDs as a 50% reduction in pain and a "moderate" response as a 30% reduction. It has been reported that a 30% reduction in pain is clinically important to patients and a lack of response of this magnitude may be the "trigger" for the following: (1) a switch to a different first-line agent. (2) combination therapy if treatment with a single drug agent fails. (Eisenberg, 2007) (Jensen, 2006) Per the guidelines, patient pain levels and functional improvement while taking medications should be documented at follow up appointments. Gabapentin specifically has good evidence to support its use, first-line, in neuropathic pain. (Backonja, 2002) (ICSI, 2007) (Knotkova, 2007) (Eisenberg, 2007) (Attal, 2006) It is FDA-approved for use in post-herpetic neuralgia. In addition to use in neuropathic pain, Gabapentin has evidence to support its use in spinal stenosis, fibromyalgia, spinal cord injury, and some evidence to support its use in post-operative pain to decrease anxiety and need for opioids. For the patient of concern, the records do indicate that patient has radicular symptoms. Furthermore, the current request is for increased dose of Gabapentin given inadequate improvement with previous dose, which is an appropriate response to a lack of improvement. As the Guidelines above indicate, the decision to continue a specific AED agent depends on efficacy and side effects. Per the records, patient has not yet reached full efficacy with the Gabapentin, so titration of the dose up is appropriate and the request for Gabapentin twice daily is considered medically necessary. Continued use of this medication would only be considered medically necessary if patient response to the increased dose is appropriately documented.